Early intervention in smoldering multiple myeloma (SMM) requires optimal risk stratification to avoid under and over-treatment. We hypothesized that replacing bone marrow (BM) plasma cells (PCs) for circulating tumor cells (CTCs), and adding immune biomarkers in peripheral blood (PB) for the identification of patients at risk of progression due to lost immune surveillance, could improve the International Myeloma Working Group 20/2/20 model.
Termini, R., Zihala, D., Terpos, E., Pérez-Montaña, A., Jelinek, T., Raab, M., et al. (2022). Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma. CLINICAL CANCER RESEARCH [10.1158/1078-0432.CCR-22-1594].
Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma
Botta, Cirino;
2022-09-08
Abstract
Early intervention in smoldering multiple myeloma (SMM) requires optimal risk stratification to avoid under and over-treatment. We hypothesized that replacing bone marrow (BM) plasma cells (PCs) for circulating tumor cells (CTCs), and adding immune biomarkers in peripheral blood (PB) for the identification of patients at risk of progression due to lost immune surveillance, could improve the International Myeloma Working Group 20/2/20 model.File | Dimensione | Formato | |
---|---|---|---|
0690800000bPvLAAA0.pdf
Solo gestori archvio
Tipologia:
Versione Editoriale
Dimensione
5.04 MB
Formato
Adobe PDF
|
5.04 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.